{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:04:27Z","timestamp":1792461867375,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010190","name":"GENCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypochondroplasia is a rare genetic form of skeletal dysplasia, caused by gain-of-function pathogenic variants in the FGF receptor 3 (FGFR3). It is characterized by disproportionate short stature and has a wide spectrum of clinical features. Currently, there are no precision therapeutic options approved for hypochondroplasia. Infigratinib is an orally bioavailable FGFR1-3 selective tyrosine kinase inhibitor in development for achondroplasia and hypochondroplasia. Infigratinib acts directly at the source of the pathophysiological cause of both conditions by inhibiting the phosphorylation of FGFR3 and attenuating both main downstream signaling pathways that are involved in the conditions. Results from a phase 2 study support the concept that infigratinib has a potential to improve bone growth in achondroplasia. We report results of a step-wise evaluation of the therapeutic relevance of infigratinib for hypochondroplasia: in silico assessment of infigratinib with hypochondroplasia associated FGFR3 variants suggest strong interaction; in vitro, infigratinib showed potent inhibitory effect; in a mouse model of hypochondroplasia (Fgfr3N534K\/+), infigratinib resulted in significant improvement in skeletal growth. These data in addition to the clinical results from the phase 2 study conducted in children with achondroplasia provide support for the development of infigratinib in the treatment of hypochondroplasia.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf088","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:34:26Z","timestamp":1750750466000},"page":"1255-1264","source":"Crossref","is-referenced-by-count":7,"title":["Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia"],"prefix":"10.1093","volume":"40","author":[{"given":"Benoit","family":"Demuynck","sequence":"first","affiliation":[{"name":"Imagine Institute, INSERM UMR 1163, Universit\u00e9 de Paris Cit\u00e9 , F-75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik P","family":"Shah","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma , QEd Therapeutics, San Francisco, 94158 CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Mayeux","sequence":"additional","affiliation":[{"name":"Imagine Institute, INSERM UMR 1163, Universit\u00e9 de Paris Cit\u00e9 , F-75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Vasseur","sequence":"additional","affiliation":[{"name":"CNRS, ITODYS, Universit\u00e9 Paris Cit\u00e9 , F-75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Barbault","sequence":"additional","affiliation":[{"name":"CNRS, ITODYS, Universit\u00e9 Paris Cit\u00e9 , F-75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Ding","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma , QEd Therapeutics, San Francisco, 94158 CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Paull","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma , QEd Therapeutics, San Francisco, 94158 CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswini","family":"Reddi","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma , QEd Therapeutics, San Francisco, 94158 CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Muslimova","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma , QEd Therapeutics, San Francisco, 94158 CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-5856","authenticated-orcid":false,"given":"Laurence","family":"Legeai-Mallet","sequence":"additional","affiliation":[{"name":"Imagine Institute, INSERM UMR 1163, Universit\u00e9 de Paris Cit\u00e9 , F-75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2025103115330915300_ref1","volume-title":"GeneReviews","author":"Bober","year":"1993-2025"},{"issue":"1","key":"2025103115330915300_ref2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajmg.a.61912","article-title":"Earlier detection of hypochondroplasia: a large single-center UK case series and systematic review","volume":"185","author":"Sabir","year":"2021","journal-title":"Am J Med Genet A"},{"issue":"12","key":"2025103115330915300_ref3","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/ajmg.a.35642","article-title":"Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation","volume":"158a","author":"Linnankivi","year":"2012","journal-title":"Am J Med Genet A"},{"key":"2025103115330915300_ref4","doi-asserted-by":"crossref","first-page":"108479","DOI":"10.1016\/j.yebeh.2021.108479","article-title":"Hypochondroplasia and temporal lobe epilepsy \u2013 a series of 4 cases","volume":"126","author":"Ahmadi","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"1","key":"2025103115330915300_ref5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.braindev.2016.07.004","article-title":"Epileptic phenotype of FGFR3-related bilateral medial temporal lobe dysgenesis","volume":"39","author":"Okazaki","year":"2017","journal-title":"Brain Dev"},{"issue":"Suppl 3","key":"2025103115330915300_ref6","first-page":"195","article-title":"Parent-reported quality of life of children with hypochondroplasia: baseline results from a clinical trial","volume":"96","author":"Rangos","year":"2023","journal-title":"Horm Res Paediatr"},{"issue":"11","key":"2025103115330915300_ref7","first-page":"1279","article-title":"FGFR3-related hypochondroplasia: longitudinal growth in 57 children with the p.Asn540Lys mutation","volume":"31","author":"Arenas","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"2025103115330915300_ref8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajmg.a.63431","article-title":"Growth reference charts for children with hypochondroplasia","volume":"194","author":"Cheung","year":"2024","journal-title":"Am J Med Genet A"},{"issue":"3","key":"2025103115330915300_ref9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng0795-357","article-title":"A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia","volume":"10","author":"Bellus","year":"1995","journal-title":"Nat Genet"},{"issue":"3","key":"2025103115330915300_ref10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ng0394-318","article-title":"A gene for achondroplasia-hypochondroplasia maps to chromosome 4p","volume":"6","author":"Le Merrer","year":"1994","journal-title":"Nat Genet"},{"issue":"7","key":"2025103115330915300_ref11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"6494","key":"2025103115330915300_ref12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/371252a0","article-title":"Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia","volume":"371","author":"Rousseau","year":"1994","journal-title":"Nature"},{"issue":"12","key":"2025103115330915300_ref13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/sj.ejhg.5201700","article-title":"Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia","volume":"14","author":"Heuertz","year":"2006","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"2025103115330915300_ref14","doi-asserted-by":"crossref","first-page":"e168796","DOI":"10.1172\/jci.insight.168796","article-title":"Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice","volume":"8","author":"Loisay","year":"2023","journal-title":"JCI Insight"},{"key":"2025103115330915300_ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411790","article-title":"Oral infigratinib therapy in children with achondroplasia","volume":"392","author":"Savarirayan","journal-title":"N Engl J Med"},{"key":"2025103115330915300_ref16","doi-asserted-by":"crossref","first-page":"116019","DOI":"10.1016\/j.bmc.2021.116019","article-title":"Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency","volume":"33","author":"Kuriwaki","year":"2021","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"2025103115330915300_ref17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/hmg\/ddr514","article-title":"A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model","volume":"21","author":"Jonquoy","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"7","key":"2025103115330915300_ref18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10822-015-9841-8","article-title":"Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3)","volume":"29","author":"Li","year":"2015","journal-title":"J Comput Aided Mol Des"},{"key":"2025103115330915300_ref19","volume-title":"Amber 2023","author":"Case","year":"2023"},{"issue":"1","key":"2025103115330915300_ref20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J Mol Graph"},{"issue":"7","key":"2025103115330915300_ref21","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J Chem Theory Comput"},{"issue":"2","key":"2025103115330915300_ref22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0021-9991(77)90121-8","article-title":"Nonphysical sampling distributions in Monte Carlo free-energy estimation: umbrella sampling","volume":"23","author":"Torrie","year":"1977","journal-title":"J Comput Phys"},{"key":"2025103115330915300_ref23","article-title":"WHAM: the weighted histogram analysis method","author":"Grossfield"},{"issue":"6","key":"2025103115330915300_ref24","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/jcb.24467","article-title":"ATDC5: an excellent in vitro model cell line for skeletal development","volume":"114","author":"Yao","year":"2013","journal-title":"J Cell Biochem"},{"issue":"11","key":"2025103115330915300_ref25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"2025103115330915300_ref26","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1073\/pnas.1814279116","article-title":"Defining a new nomenclature for the structures of active and inactive kinases","volume":"116","author":"Modi","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2025103115330915300_ref27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"10 Pt B","key":"2025103115330915300_ref28","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbapap.2015.03.009","article-title":"The ABC of protein kinase conformations","volume":"1854","author":"M\u00f6bitz","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2025103115330915300_ref29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2025103115330915300_ref30","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI83926","article-title":"Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model","volume":"126","author":"Komla-Ebri","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"2025103115330915300_ref31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jbmr\/zjae051","article-title":"Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model","volume":"39","author":"Demuynck","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2025103115330915300_ref32","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/jbmr\/zjae173","article-title":"Achondroplasia: aligning mouse model with human clinical studies shows crucial importance of immediate postnatal start of the therapy","volume":"39","author":"Rico-Llanos","year":"2024","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf088\/63564794\/zjaf088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/11\/1255\/63564794\/zjaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/11\/1255\/63564794\/zjaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T19:33:15Z","timestamp":1761939195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/11\/1255\/8172361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf088","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,24]]}}}